FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
GE	A1.	6,096,737	8/1/2000	Loder	514	217	
	A2.	6,475,743	11/5/2002	Bar-Or et al.	435	7.1	
	A3.	6,555,543	4/29/2003	Bar-Or et al.	514	255.02	
	A4.	6,492,179	12/10/2002	Bar-Or et al.	436	74	
	A5.	6,461,875	10/8/2002	Bar-Or et al.	436	536	
	A6.	6,090,780	7/18/2000	Prasad	514	11	
	A7.	4,771,056	9/13/1988	Rozencwaig	514	325	
	A8.	4,661,500	4/28/1987	Rozencwaig	514	325	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
GE	A9.	WO 02/11676	2/14/2002	PCT				
	A10.	NZ 033544	8/31/2001	New Zealand				
	A11.	EP 0 835 660 A1	4/15/1998	EPO				
	A12.	EP 0 214 557 A2	3/18/1987	EPO				
	A13.	EP 0 214 557 A3	3/18/1987	EPO				
	A14.	WO 01/34586	5/17/2001	PCT				
	A15.	WO 00/20454	4/13/2000	PCT				

EXAMINER /Gregory Emch/	DATE CONSIDERED 08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

							TRANSLATION	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS		
GE	A16.	WO 02/059604	8/1/2002	PCT				
	A17.	WO 00/20840 A1	4/13/2000	PCT				
	A18.	WO 98/40748 A1	9/17/1998	PCT				
	A19.	RU2112242C1	5/27/1998	Russian Federation			X, abstract only	
	A20.	RU2125728C1	1/27/1999	Russian Federation			X, abstract only	
	A21.	RU2128840C1	4/10/1999	Russian Federation			X, abstract only	

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

GE	A22.	Esposito et al., "The Solution Structure of the C-Terminal Segment of Tau Protein," *Journal of Peptide Science* 2000, 6:550-559
	A23.	Gamblin et al., "Tau Polymerization: Role of the Amino Terminus," *Biochemistry* 2003, 42(7):2252-2257
	A24.	Crowe et al., "The N Terminal Region of Human Tau is Present in Alzheimer's Disease Protein A68 and is Incorporated into Paired Helical Filaments," *American Journal of Pathology* 1991, 139(6):1463-1470
	A25.	Berry et al., "Inhibition of Tau Polymerization by its Carboxy-Terminal Caspase Cleavage Fragment," *Biochemistry* 2003, 42:8325-8331
	A26.	Abraha et al., C-terminal inhibition of tau assembly *in vitro* and in Alzheimer's disease," *Journal of Cell Science* 2000, 113:3737-3745
	A27.	Bar-Or et al., "An Analog of the Human Albumin N-Terminus (Asp-Ala-His-Lys) Prevents Formation of Copper-Induced Reactive Oxygen Species," *Biochemical and Biophysical Research Communications* 2001, 284(3):856-862

EXAMINER /Gregory Emch/	DATE CONSIDERED 08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

GE	A28.	Bar-Or et al., "Potential Plasma Surrogate Biomarkers for CNS Demyelinating Processes," Meeting of the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Sept. 17-20, 2003 (abstract first distributed at the meeting)
	A29.	Garcia-Sierra et al., "Conformational Changes and Truncation of Tau Protein During Tangle Evolution in Alzheimer's Disease," *Journal of Alzheimer's Disease* 2003, 5:65-77
	A30.	Hasegawa et al., "Protein Sequence and Mass Spectrometric Analysis of Tau in the Alzheimer's Disease Brain," *Journal of Biological Chemistry* 1992, **267**(24):17047-17054
	A31.	Shutov et al., "[Diagnostic Significance of the type of In Vitro Interaction between Blood Lymphocytes and Serotonin in Multiple Sclerosis]" [Article in Russian], *Zh Nevrol Psikhiatr Im S S Korsakova* 2002, **102**(4):35-38, **Abstract only**, from PubMed - PMID:12001663
	A32.	Lechin et al., "Plasma Neurotransmitters and Cortisol in Chronic Illness: Role of Stress," *J Medicine* 1994, **25**(3-4):181-192, **Abstract only**, from PubMed -PMID:7996062
	A33.	Takahara et al., "Detection in Human Serum by Radioimmunoassay of Histidyl-Proline Diketopiperazine, a Metabolite of Thyrotropin-Releasing Hormone," *J Clinical Endocrinology* 1983, **56**(2):312-319, **Abstract only**, from PubMed -PMID:6401750
	A34.	Prasad, "Bioactive Cyclic Dipeptides," *Peptides* 1995, **16**:151-164
	A35.	Jicha et al., "Sequence Requirements for Formation of Conformational Variants of Tau Similar to Those Found in Alzheimer's Disease," *Journal of Neuroscience Research* 1999, **55**:713-723
	A36.	Murray et al., "Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro," *Biochemistry* 2003, **42**:8530-8540
	A37.	Steiner et al., "Histidyl Proline Diketopiperazine (Cyclo [His-Pro]) in Eating Disorders," *Neuropeptides* 1989, **14**(3):185-189, **Abstract only**, from PubMed -PMID:2615922
	A38.	Prasad et al., "Isolation of cyclo(His-Pro)-like immunoreactivity from Human Urine and Demonstration of its Immunologic, Pharmacologic, and Physico-chemical Identity with the Synthetic Peptide," *Biochemistry Int* 1990, **21**(3):425-434, **Abstract only**, from PubMed -PMID:2222490
	A39.	Hilton et al., "Food Contains the Bioactive Peptide, Cyclo(His-Pro), *J Clinical Endocrinol Metab* 1992, **75**(2):375-378, **Abstract only**, from PubMed -PMID:1639938
↓	A40.	Banks et al., "Radioactively Iodinated Cyclo(His-Pro) Crosses the Blood-Brain Barrier and Reverses Ethanol-Induced Narcosis," *American J Physiol* 1993, **264**(5 Pt 1):E723-729, **Abstract only**, from PubMed -PMID:8498494

EXAMINER /Gregory Emch/	DATE CONSIDERED 08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

GE	A41.	Duntas et al., "A Fast Protein Liquid Chromatography (FPLC) Method for Study of Thyrotropin-releasing Hormone (TRH) and its metabolite Histidyl-Proline Diketopiperazine (CHP) in Human Blood: Degradation in Liver and Pancreatic Diseases," *Neuropeptides* 1993 **25**(6):357-361, **Abstract only**, from PubMed -PMID:8127415
	A42.	Shukla et al., "Role of Endogenous Cyclo(His-Pro) in Cold-Induced Hypothermia in the Desert Rat (Mastomys natalensis)," *Peptides* 1994, **15**(8):1471-1474, **Abstract only**, from PubMed -PMID:7700849
	A43.	Jaspan et al., "Study of Passage of Peptides Across the Blood-Brain Barrier: Biological Effects of Cyclo(His-Pro) After Intravenous and Oral Administration, *Annals of the New York Academy of Science* 1994, **739**:101-107, **Abstract only**, from PubMed -PMID:7832464
	A44.	Wolf et al., "Identification of Cyclo(His-Pro)-Like Immunoreactivity in Human Follicular Fluid: Correlation with Steroid and Peptide Hormones," *J Soc Gynecol Investigation* 1994, **1**(3):220-224, **Abstract only**, from PubMed -PMID:9419775
	A45.	Fragner et al., "A New Biological Contribution of Cyclo(His-Pro) to the Peripheral Inhibition of Pancreatic Secretion," *American Journal of Physiology* 1997, **273**(6 Pt 1):E1127-32, **Abstract only**, from PubMed -PMID:9435528
	A46.	Yamada et al., "Abundance of Cyclo (His-Pro)-Like Immunoreactivity in the Brain of TRH-deficient Mice," *Endocrinology* 1999, **140**(1):538-541, **Abstract only**, from PubMed -PMID:9886867
	A47.	Parker et al., "Evidence for the Presence of Immunoreactive Histidyl-Proline Diketopiperazine [Cyclo (His-Pro)] in the Adult Human Brain," *Peptides* 1983, **4**(6):879-881, **Abstract only**, from PubMed -PMID:6672793
	A48.	Youngblood et al., "Bovine Serum Albumin-GABA-His-Pro-NH2: an Immunogen for Production of Higher Affinity Antisera for TRH," *J Neursci Methods* 1983, **9**(4):367-373, **Abstract only**, from PubMed -PMID:6422166
	A49.	Lechan et al., "Thyrotropin Releasing Hormone but not Histidyl-Proline Diketopiperazine is Depleted from Rat Spinal Cord Following 5,7-Dihydroxytryptamine Treatment," *Brain Research* 1985, **326**(1):152-155, **Abstract only**, from PubMed -PMID:3918765
	A50.	Diamanti Kandarakis et al., "Distribution and Characterization of Cyclo (His-Pro)-Like Immunoreactivity in the Human Gastrointestinal Tract," *Neuropeptides* 1985, **6**(1):21-5, **Abstract only**, from PubMed -PMID:3990923
	A51.	Pekary et al., "In vitro Production of a TRH-Homologous Peptide and His-Pro Diketopiperazine by Human Semen," *J Androl* 1985, **6**(6):379-385, **Abstract only**, from PubMed -PMID:3935636
	A52.	Koskinen, "Effect of Low Intravenous Doses of TRH, Acid-TRH and Cyclo (His-Pro) on Cerebral and Peripheral Blood Flows," *British Journal of Pharmacology* 1986, **87**(3):509-519, **Abstract only**, from PubMed -PMID:3099875
	A53.	Prasad et al., "Distribution and Characterization of Cyclo (His-Pro)-Like Immunoreactivity in Human Cerebrospinal Fluid," *Biochem Biophys Res Commun* 1986, **136**(2):835-842, **Abstract only**, from PubMed -PMID:2871837

EXAMINER	/Gregory Emch/	DATE CONSIDERED	08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

GE	A54.	Kurahashi et al., ["Histidyl-Proline Diketopiperazine (HPD) a Metabolite of Thyrotripin-Releasing Hormone (TRH), Improves the Ataxic Gait in 3-Acetylpyridine (3-AP) Treated Rats"] [Article in Japanese] *No To Shineki* 1986, **38**(9):893-898, **Abstract only**, from PubMed -PMID:3790371
	A55.	Coggins et al., "High Affinity Specific Binding of the Thyrotrophin Releasing Hormone Metabolite Histidylproline to Rat Brain Membranes," *Neuropeptides* 1987, **9**(1):83-91, **Abstract only**, from PubMed -PMID:3104816
	A56.	Mori et al., "Specific Radioimmunoassay of Cyclo (His-Pro), a Biologically Active Metabolite of Thyrotropin-Releasing Hormone," *Endocrinology* 1981, **108**(5):1995-1997, **Abstract only**, from PubMed -PMID:6783397
	A57.	Mori et al., "Regional Dissociation of Histidyl-Proline Diketopiperazine (Cyclo-(His–Pro)) and Thyrotropin-Releasing Hormone (TRH) in the Rat Brain," *Brain Research* 1982, **231**(2):451-453, **Abstract only**, from PubMed -PMID:6799149
	A58.	Prasad et al., "Distribution and Metabolism of Cyclo (His-Pro): a New Member of the Neuropeptide Family," *Peptides* 1982, **3**(3):591-598, **Abstract only**, from PubMed -PMID:6812031
	A59.	Mori et al., "Histidyl-Proline Diketopiperazine Cyclo (His-Pro): Identification and Characterization in Rat Pancreatic Islets," *Biochem Biophys Res Commun* 1983, **115**(1):281-286, **Abstract only**, from PubMed -PMID:6351862
	A60.	Mitsuma et al., "Radioimmunoassay for Thyrotropin-Releasing Hormone Precursor Peptide, Lys-Arg-Gln-His-Pro-Gly-Arg-Arg," *Exp Clin Endocrinology* 1989, **93**(1):53-60, **Abstract only**, from PubMed -PMID:2500352
	A61.	Gu et al., "Diketopiperazine Formation, Hydrolysis, and Epimerization of the New Dipeptide Angiotensin-Converting Enzyme Inhibitor RS-10085," *Pharm Res* 1987, **4**(5):392-397, **Abstract only**, from PubMed -PMID:3508548
	A62.	Guerra et al., "PEGylation Prevents the N-Terminal Degradation of Megakaryocyte Growth and Development Factor," *Pharm Res* 1998, **15**(12):1822-1827, **Abstract only**, from PubMed -PMID:9892464
	A63.	Sepetov et al., "Rearrangement, Racemization and Decomposition of Peptides in Aqueous Solution," *Peptide Research* 1991, **4**(5):308-313, **Abstract only**, from PubMed -PMID:1802242
	A64.	Reubsaet et al., "Qualitative and Quantitative Aspects of the Degradation of Several Tripeptides Derived from the Antitumor Peptide Antagonist [Arg(6), D-Trp(7,9), MePhe(8)] Substance P[6-11]," *J Pharm Biomed Anal* 1999, **19**(3-4):277-284, **Abstract only**, from PubMed -PMID:10704092
	A65.	Song et al., "Synergistic Antidiabetic Activities of Zinc, Cyclo (His-Pro), and Arachidonic Acid," *Metabolism* 2001 **50**(1):53-59, **Abstract only**, from PubMed -PMID:11172475
↓	A66.	Rosenthal et al., "Effects of Arachidonic Acid and Cyclo (His-Pro) on Zinc Transport Across Small Intestine and Muscle Tissues," *Life Sci* 2001, **70**(3):337-348, **Abstract only**, from PubMed -PMID:12005266

EXAMINER /Gregory Emch/	DATE CONSIDERED 08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

GE		A67.	Pandey et al., "Synthetic Peptides Corresponding to a Repetitive Sequence of Malarial Histidine Rich Protein Bind Haem and Inhibit Haemozoin Formation in vitro," *Mol Biochem Parasitol* 1997, **90**(1):281-287, **Abstract only**, from PubMed -PMID:9497049
		A68.	Baig et al., "High Performance Liquid Chromatography as a Tool in the Definition of Abnormalities in Monamine and Tryptophan Metabolites in Cerebrospinal Fluid from Patients with Neurological Disorders," *Biomed Chromatogr* 1991, **5**(3):108-112, **Abstract only**, from PubMed -PMID:1863084
		A69.	Monaco et al., "Plasma and cerebrospinal fluid tryptophan in Multiple Sclerosis and Degenerative Diseases," *J Neurol Neurosurg Psychiatry* 1979 **42**(7):640-1, **Abstract only**, from PubMed -PMID:479903
		A70.	Scharpe et al., "Peptide Truncation by Dipeptidyl Peptidase IV: A New Pathway for Drug Discovery," *Verh K. Acad Geneeskd Belg.* 2001, **63**(1):5-32, **Abstract only**, from PubMed -PMID:11284388
		A71.	Mentlein et al., "Dipeptidyl-Peptidase IV Hydrolyses Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)amide, Peptide Histidine Methionine and is Responsible for their Degradation in Human Serum," *European Journal of Biochemistry* 1993, **214**(3):829-835, **Abstract only**, from PubMed -PMID:8100523
		A72.	Hilton et al., "Radioimmunoassay of Cyclo(His-Pro) in Unextracted Human Plasma: Report of a Normal Range and Definition of Factors Critical for Successful Assay," *Neuropeptides* 1989, **13**(1):65-70, **Abstract only**, from PubMed -PMID:2922107
		A73.	Iriuchijima et al., "Thyrotripin-Releasing Hormone and Cyclo (His-Pro)-Like Immunoreactivities in the Cerebrospinal Fluids of 'Normal' Infants and Adults, and Patients with Various Neuropsychiatric and Neurologic Disorders," *Life Sci.* 1987, **41**(22):2419-2428, **Abstract only**, from PubMed -PMID:2891013
		A74.	Hilton et al., "Relationship between Plasma Cyclo (His-Pro), a Neuropeptide Common to Processed Protein-Rich Food, C-Peptide/Insulin Molar Ratio in Obese Women," *Nutr Neurosci* 2001, **4**(6):469-474, **Abstract only**, from PubMed -PMID:11843266
		A75.	Mori et al., "Brain TRH and Cyclo (His-Pro) and Brain Protein in the Newborn Rat are Altered by Maternal Liquid Protein Feeding," *Life Sci* 1983, **32**(14):1607-1612, **Abstract only**, from PubMed -PMID:6403790
		A76.	Mori et al., ["TRH and Cyclo (His-Pro) Concentrations in the Young Rat Brain are Altered by a Liquid Protein Diet]" [Article in Japanese], *Nippon Naibunpi Gakkai Zasshi* 1987, **63**(7):846-852
		A77.	Mori et al., "Alteration by Liquid Protein Diet of TRH and Cyclo(His-Pro) in the Young Rat Brain," *Res. Commun Chem Pathol Pharmacol* 1985, **47**(1):157-160, **Abstract only**, from PubMed -PMID:392073
↓		A78.	Goolcharran et al., "Comparison of the Rates of Deamidation, Diketopiperazine Formation and Oxidation in Recombinant Human Vascular Endothelial Growth Factor and Model Peptides," *AAPS PharmSci* 2000, **2**(1)E5, **Abstract only**, from PubMed -PMID:11741221

EXAMINER	/Gregory Emch/	DATE CONSIDERED	08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

GE	A79.	Moss et al., "Kinetics and Mechanism of the Facile Cyclization of Histidyl-Prolineamide to Cyclo (His-Pro) In Aqueous Solution and the Competitive Influence of Human Plasma," *J Pharm Pharmacol* 1990, **42**(1):7-12, **Abstract only**, from PubMed -PMID:1969958
	A80.	Hilton et al., "Identification and Characterization of Cyclo (His-Pro)-Like Immunoreactivity in Amniotic Fluid," *Peptides* **10**(2):299-301, **Abstract only**, from PubMed -PMID:2755872
	A81.	Bhargava et al., "Inhibition of Neuroleptic-Induced Dopamine Receptor Supersensitivity by Cyclo (Leu-Gly)," *Pharmacol Biochem Behav* 1980, **13**(5):633-636, **Abstract only**, from PubMed -PMID:7443732
	A82.	Leduque et al., "Histidyl-Proline Diketopiperazine (His-Pro DKP) Immunoreactivity is Present in the Glucagon-Containing Cells of the Human Fetal Pancreas," *J Clin Invest* 1987, **79**(3):875-880, **Abstract only**, from PubMed -PMID:3102558
	A83.	Battersby et al., "Diketopiperazine Formation and N-Terminal Degradation in Recombinant Human Growth Hormone," *Int J Peptide Protein Res* 1994, **44**(3):215-222, **Abstract only**, from PubMed -PMID:7822097
	A84.	Bhargava et al., "Inhibition of Neuroleptic-Induced Dopamine Receptor Supersensitivity by Cyclo (Leu-Gly)," *Pharmacol. Biochem Behav* 1980, **13**(5):633-636, **Abstract only**, from PubMed -PMID:7443732
	A85.	Yanagisawa et al., "The Subcellular and Organ Distribution and Natural Form of Histidyl-Proline Diketopiperazine in Rat brain Determined by a Specific Radioimmunoassay," *J Biol Chem* 1980, **255**(21):10290-10294, **Abstract only**, from PubMed -PMID:7430126
	A86.	Hoffman et al., "An Enzymatically Stable Peptide with Activity in the Central Nervous System: Its Penetration Through to Blood-CSF Barrier," *Brain Res.* 1977, **122**(1):87-94, **Abstract only**, from PubMed -PMID:837226
	A87.	Meester et al., "In Vivo Inhibition of Dipeptidyl Peptidase IV Activity by Pro-Pro-diphenyl-phosphonate (Prodipine)", *Biochemical Pharmacology* 1997, **54**:173-179
	A88.	Prasad et al., "Thermoregulation in rats: opposing effects of thyrotropin releasing hormone and its metabolite histidyl-proline diketopiperazine," *Biochem Biophys Res. Commun.* 1978, **85**(4):1582-187
	A89.	Wilber et al., "Histidyl-proline diketopiperazine: a potent and chronic appetite-inhibiting neuropeptide," *Trans Assoc. Am Physicians* 1986, **99**:245-249
	A90.	Wilber et al., "Endogenous histidyl-proline diketopiperazine [cyclo (His-Pro)]: a potential satiety neuropeptide in normal and genetically obese rodents," *Trans Assoc Am Physicians* 1983, **96**:131-136
	A91.	Bhargava, "Inhibition of abstinence syndrome in opiate dependent mice by cyclo (His-Pro), *Life Sci* 1981, **28**(11):1261-1267
↓	A92.	Bhargava, "The effects of thyrotropin releasing hormone and histidyl-proline diketopiperazine on delta-9-tetrahydrocannabinol-induced hypothermia," *Life Sci* 1980, **26**(11):845-850

EXAMINER /Gregory Emch/	DATE CONSIDERED 08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1649

GE	A93.	Bhargava, "Antagonism of ketamine-induced anesthesia and hypothermia by thyrotropin releasing hormone and cyclo (His-Pro)," *Neuropharmacology* 1981, **20**(7):699-702
	A94.	Mori et al., "Histidyl-Proline Diketopiperazine cyclo (His-Pro): measurement by radioimmunoassay in human blood in normal subject and in patients with hyper- and hypothyroidism," *Biochem Biophys Res Commun* 1982, **109**(2):541-547
	A95.	Luca et al., "Determination of serotonin content and ceruloplasmin activity, of blood and CSF amino acid level in multiple sclerosis," *Neurol Psychiatr (Bucur)* 1986, **24**(3):153-159
	A96.	Mori et al., "Distribution of histidyl-proline diketopiperazine [cyclo (His-Pro)] and thyrotropin-releasing hormone (TRH) in the primate central nervous system," *Brain Res* 1982, **245**(1):183-186

EXAMINER /Gregory Emch/	DATE CONSIDERED 08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known	
Application Number	10/679,699
Filing Date	October 2, 2003
First Named Inventor	
Art Unit	1649
Examiner Name	G.S.Emch
Attorney Docket Number	4172-85

Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GE		US-6,815,214 B2	11-09-2004	Boyce, et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]; Number[4]; Kind Code[5] (if known)			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		PCT	-					
			-					

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No.[1]	
GE		Montine et al., Cerebrospinal Fluid Ab42, Tau, and F2-Isoprostane Concentrations in Patients with Alzheimer Disease, Other Dementias, and in Age-Matched Controls, Acrch Pathol Lab. Med, April 2001, Vol. 125, pages 510-512.
		Wennemers et al., Diketopiperazine Receptors: A Novel Class of Highly Selective Receptors for Binding Small Peptides, Chem. Eur. J. 2001, Vol. 7, No. 15, pages 3342-3347.
		Prakash et al., Synthesis and Biological Activity of Novel Neuroprotective Diketopiperazines, Bioorganic & Medicinal Chemistry, September 2002, Vol. 10, No. 9, pages 3043-3048.
		McCleland et al., An investigation into the biological activity of the selected histidine-containing diketopieperazines cyclo(His-Phe) and cyclo(His-Tyr), Journal of Pharmacy and Pharmacology, September 2004, Vol. 56, No. 9, pages 1143-1153.

Examiner Signature	/Gregory Emch/	Date Considered	08/22/2006

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

IDS - 06/06/2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10679699
Filing Date	2003-10-02
First Named Inventor	David Bar-Or
Art Unit	1649
Examiner Name	Gregory Emch
Attorney Docket Number	4172-85

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
GE	1	2004034060	WO	A2	2004-04-22	Van Eyk, et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10679699
	Filing Date	2003-10-02
	First Named Inventor	David Bar-Or
	Art Unit	1649
	Examiner Name	Gregory Emch
	Attorney Docket Number	4172-85

	1		☐

If you wish to add additional non-patent literature document citation information please click the Add button [Add]

EXAMINER SIGNATURE

Examiner Signature	/Gregory Emch/	Date Considered	08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.